Capricor Therapeutics, Inc.
CAPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $11 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $20 | $22 | $19 | $15 |
| Gross Profit | -$20 | -$22 | -$19 | -$3 |
| % Margin | – | – | – | -30.8% |
| R&D Expenses | $20 | $22 | $19 | $15 |
| G&A Expenses | $6 | $6 | $6 | $4 |
| SG&A Expenses | $6 | $6 | $6 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$20 | -$22 | -$19 | -$15 |
| Operating Expenses | $6 | $6 | $6 | $4 |
| Operating Income | -$26 | -$28 | -$25 | -$8 |
| % Margin | – | – | – | -69.2% |
| Other Income/Exp. Net | $2 | $2 | $1 | $1 |
| Pre-Tax Income | -$25 | -$26 | -$24 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25 | -$26 | -$24 | -$7 |
| % Margin | – | – | – | -63.9% |
| EPS | -0.54 | -0.57 | -0.53 | -0.16 |
| % Growth | 5.3% | -7.5% | -231.3% | – |
| EPS Diluted | -0.54 | -0.57 | -0.53 | -0.16 |
| Weighted Avg Shares Out | 46 | 46 | 46 | 35 |
| Weighted Avg Shares Out Dil | 46 | 46 | 46 | 35 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$24 | -$27 | -$25 | -$7 |
| % Margin | – | – | – | -65.8% |